Array BioPharma Inc. (ARRY) Rating Reiterated by Cowen and Company

Array BioPharma Inc. (NASDAQ:ARRY)‘s stock had its “outperform” rating restated by equities researchers at Cowen and Company in a research report issued on Monday. They currently have a $15.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $14.00. Cowen and Company’s price objective suggests a potential upside of 50.45% from the stock’s current price.

A number of other research analysts have also commented on ARRY. Cantor Fitzgerald set a $13.00 price objective on Array BioPharma and gave the company a “buy” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies reiterated a “buy” rating and issued a $14.00 price objective on shares of Array BioPharma in a research report on Thursday, August 10th. Zacks Investment Research upgraded Array BioPharma from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $13.00 price objective on shares of Array BioPharma in a research report on Thursday, August 10th. Finally, BidaskClub lowered Array BioPharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company’s stock. Array BioPharma has a consensus rating of “Buy” and an average target price of $12.65.

Shares of Array BioPharma (ARRY) opened at 9.97 on Monday. Array BioPharma has a one year low of $3.42 and a one year high of $13.40. The firm’s market cap is $1.71 billion. The stock has a 50 day moving average price of $8.80 and a 200 day moving average price of $8.81.

Array BioPharma (NASDAQ:ARRY) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.04. The firm had revenue of $33.80 million for the quarter, compared to analyst estimates of $28.64 million. Array BioPharma had a negative return on equity of 1,187.18% and a negative net margin of 77.44%. The business’s quarterly revenue was down 21.8% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS. On average, equities research analysts forecast that Array BioPharma will post ($0.99) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/2887713/array-biopharma-inc-arry-rating-reiterated-by-cowen-and-company.html.

Large investors have recently bought and sold shares of the company. Fisher Asset Management LLC boosted its position in shares of Array BioPharma by 72.0% in the 2nd quarter. Fisher Asset Management LLC now owns 134,180 shares of the biopharmaceutical company’s stock worth $1,123,000 after purchasing an additional 56,166 shares during the last quarter. Alambic Investment Management L.P. boosted its position in shares of Array BioPharma by 12.6% in the 1st quarter. Alambic Investment Management L.P. now owns 195,030 shares of the biopharmaceutical company’s stock worth $1,744,000 after purchasing an additional 21,800 shares during the last quarter. Spark Investment Management LLC boosted its position in shares of Array BioPharma by 30.9% in the 1st quarter. Spark Investment Management LLC now owns 343,900 shares of the biopharmaceutical company’s stock worth $3,074,000 after purchasing an additional 81,200 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Array BioPharma in the 1st quarter worth $1,242,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Array BioPharma in the 1st quarter worth $303,000. Institutional investors and hedge funds own 97.60% of the company’s stock.

About Array BioPharma

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Analyst Recommendations for Array BioPharma (NASDAQ:ARRY)

Receive News & Ratings for Array BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.